Created On: 2020-07-15
Record Count: 7
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 27122
term 'Licensed Products' means products containing Monoclonal Antibodies defined above and promoted and labelled for use as laboratory reagents.
IPSCIO Record ID: 27645
Patents on pritumumab (aka, CLNH11/CLNIgG; plus CLNH5)
4,618,577 – human-human hybridoma, CLNH5
4,761,377 – human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells
5,093,261 – cancer-related antigen-specific human immunoglobulins and human/human hybridomas having the ability to produce said human immunoglobulins
5,155,036 – serum-free medium containing retinoic acid useful for cultivating human/human hybridomas
5,286,647 – human-human hybridomas for neoplasms
5,589,573 – amino acid sequences of anti-idiotypic antibodies against anti-cancer human monoclonal antibody, and DNA base sequences encoding those sequences.
5,602,027 – cell line TRIH8 obtained by the fusion of the human epidermoid carcinoma cell line A431 with the TOS/H8 hybridoma.
6,051,229 – human-humann hybridoma for neoplasms CLNH5 and CLNH11 specific antibody compositions
6,051,387 – methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies
6,051,693 – CLNH11-specific antibodies
6,090,924 – human-human CLNH5-specific antibodies
6,165,467 – stabilized human monoclonal antibody preparation
The goal of the Licensee is to become a leading oncology-focused biopharmaceutical company
IPSCIO Record ID: 163133
In order to protect Licensees source of supply of the Cell Lines or Derivatives Licensor warrants and agrees that Licensor shall maintain the Cell Lines and Derivatives in such a manner as will best preserve the viability thereof, in accordance with established scientific procedures.
Monoclonal Antibodies to Human Interferongamma:
*1. Antibody B133.5
2. Antibody 3C11C8
3. Antibody 2G1
Monoclonal Antibodies to Human Granulocyte Marophage-Colony Stimulating Factor:
1. Antibody 3092
2. Antibody 3034
3. Antibody 1089
4. Antibody 4117
5. Antibody 2118
6. Antibody 1028
Monoclonal Antibodies to Human Tumor Necrosis Factor-alpha:
*1. Antibody B154.7.1
*2. Antibody B154.9.1
IPSCIO Record ID: 29291
IPSCIO Record ID: 6804
The Licensor provides vital products and services to facilitate the discovery, development and production of human and animal diagnostics and therapeutics. Their portfolio includes diagnostic controls, plasma-derived reagents and molecular biomarkers, biobanking and contract research services.
IPSCIO Record ID: 26091
Developed Patent Rights shall mean any and all patents and patent applications anywhere in the world which contains one or more claims directed to Technology, which is not an Existing Patent Right.
Technology shall mean any and all existing or future information, technical data, inventions, discoveries or know-how, and materials whether or not patented or patentable, related to or useful for the identification, isolation, purification, propagation or of use of mesenchymal stem cells and/or cells or products derived from or produced by mesenchymal stem cells, which are conceived, developed or reduced to practice by an Investigator while performing research at the University.
IPSCIO Record ID: 7481
Biological Property shall mean any DNA materials, derivatives of such DNA materials, cell lines and peptides containing the DNA materials or derivatives thereof, that are related to the TGF-B Antibody Patent Rights, and to the TGF-B Receptor Patent Rights, respectively.
TGF-B Antibody Patent Rights shall mean the Patent Rights that relate to monoclonal antibodies that bind Transforming Growth Factor ('TGF-B'), specifically TGF-B1 and TGF-B2.
TGF-B Receptor Patent Rights Licensed from MIT shall mean the Patent Rights that relate to TGF-B receptors, including TGF-B type II and TGF-B type III receptors, cDNA of the respective receptors, and methods of use.